Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Francis J. Giles

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalTargeted Oncology
Volume4
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Pericardial Effusion
Pleural Effusion
Protein-Tyrosine Kinases
Inflammation
Natural Killer T-Cells
Platelet-Derived Growth Factor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phosphotransferases
Physicians
Therapeutics
Neoplasms
Dasatinib
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Pleural/pericardial effusions

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. / Kelly, Kevin; Swords, Ronan; Mahalingam, Devalingam; Padmanabhan, Swaminathan; Giles, Francis J.

In: Targeted Oncology, Vol. 4, No. 2, 04.2009, p. 99-105.

Research output: Contribution to journalArticle

Kelly, K, Swords, R, Mahalingam, D, Padmanabhan, S & Giles, FJ 2009, 'Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors', Targeted Oncology, vol. 4, no. 2, pp. 99-105. https://doi.org/10.1007/s11523-009-0110-4
Kelly, Kevin ; Swords, Ronan ; Mahalingam, Devalingam ; Padmanabhan, Swaminathan ; Giles, Francis J. / Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. In: Targeted Oncology. 2009 ; Vol. 4, No. 2. pp. 99-105.
@article{f1a27061e408487090e8eb5fa4b93528,
title = "Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors",
abstract = "Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.",
keywords = "Chronic myeloid leukemia, Dasatinib, Pleural/pericardial effusions",
author = "Kevin Kelly and Ronan Swords and Devalingam Mahalingam and Swaminathan Padmanabhan and Giles, {Francis J.}",
year = "2009",
month = "4",
doi = "10.1007/s11523-009-0110-4",
language = "English (US)",
volume = "4",
pages = "99--105",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

AU - Kelly, Kevin

AU - Swords, Ronan

AU - Mahalingam, Devalingam

AU - Padmanabhan, Swaminathan

AU - Giles, Francis J.

PY - 2009/4

Y1 - 2009/4

N2 - Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

AB - Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Pleural/pericardial effusions

UR - http://www.scopus.com/inward/record.url?scp=67349222815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349222815&partnerID=8YFLogxK

U2 - 10.1007/s11523-009-0110-4

DO - 10.1007/s11523-009-0110-4

M3 - Article

C2 - 19381453

AN - SCOPUS:67349222815

VL - 4

SP - 99

EP - 105

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -